nach oben

Current Fungal Infection Reports

Erschienen in:

09.05.2018 | Pediatric Fungal Infections (E Roilides, Section Editor)

Prevention of Invasive Candidiasis in Premature Neonates: Administering Fluconazole or Not?

verfasst von: Daniele Donà, Dora Luise, Eugenio Baraldi, Ursula Trafojer

Erschienen in: Current Fungal Infection Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

Fluconazole prophylaxis (FP) for invasive candidiasis (IC) in preterm newborns is still a debated topic. In this review, we describe the most important papers on the topic, and we discuss pros and cons of the use FP in newborns according to these paper’s findings.

Recent Findings

Since 2001, several studies have been published on the use of FP to prevent IC. While most of them agree on the effectiveness of FP in reducing IC, especially in NICUs with high IC rates, the lack of evidence of decrease in overall mortality, and the risks associated with fluconazole administration both concerning neurodevelopmental impairment and the increase in Candida resistances still pose great concern against the universal implementation of FP.

Summary

A local risk-based selection strategy could represent the best choice to optimize the benefits of FP and minimize the potential long-term toxicity and the development of resistant pathogens.

Wynn JL, Benjamin DK Jr, Benjamin DK, Cohen-Wolkowiez M, Clark RH, Smith PB. Very late onset infections in the neonatal intensive care unit. Early Hum Dev. 2012;88(4):217–25. https://doi.org/10.1016/j.earlhumdev.2011.08.009.CrossRefPubMed

Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117(1):84–92.CrossRefPubMed

Adams-Chapman I, Bann CM, Das A, Goldberg RN, Stoll BJ, Walsh MC, et al. Neurodevelopmental outcome of extremely low birth weight infants with Candida infection. J Pediatr. 2013;163(4):961–7.e3. https://doi.org/10.1016/j.jpeds.2013.04.034.CrossRefPubMedPubMedCentral

Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J. 2000;19(4):319–24.CrossRefPubMed

Ghazal P, Dickinson P, Smith CL. Early life response to infection. Curr Opin Infect Dis. 2013;26(3):213–8. https://doi.org/10.1097/QCO.0b013e32835fb8bf.CrossRefPubMed

Brady MT. Health care-associated infections in the neonatal intensive care unit. Am J Infect Control. 2005;33(5):268–75.CrossRefPubMed

Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118:717–22.CrossRefPubMed

Donà D, Mozzo E, Mardegan V, Trafojer U, Lago P, Salvadori S, et al. Antibiotics prescriptions in the neonatal intensive care unit: how to overcome everyday challenges. Am J Perinatol. 2017;34(12):1169–77. https://doi.org/10.1055/s-0037-1602426.CrossRefPubMed

Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis. 1994;13(4):325–9.CrossRefPubMed

10.

Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345(23):1660–6.CrossRefPubMed

11.

Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics. 2001;107:293–8.CrossRefPubMed

12.

Manzoni P, Stolfi I, Pugni L, Decembrino L, Magnani C, Vetrano G, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356:2483–95.CrossRefPubMed

13.

Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics. 2008;121:703–10.CrossRefPubMed

14.

Parikh TB, Nanavati RN, Patankar CV, Rao S, Bisure K, Udani RH, et al. Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants. Indian Pediatr. 2007;44(11):830–7.PubMed

15.

Lee J, Kim HS, Shin SH, Choi CW, Kim EK, Choi EH, et al. Efficacy and safety of fluconazole prophylaxis in extremely low birth weight infants: multicenter pre-post cohort study. BMC Pediatr. 2016 May 16;16:67. https://doi.org/10.1186/s12887-016-0605-y.CrossRefPubMedPubMedCentral

16.

Benjamin DK Jr, Hudak ML, Duara S, Randolph DA, Bidegain M, Mundakel GT, et al. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. JAMA. 2014;311(17):1742–9. https://doi.org/10.1001/jama.2014.2624.CrossRefPubMedPubMedCentral

17.

Bertini G, Perugi S, Dani C, Filippi L, Pratesi S, Rubaltelli FF. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr. 2005;147:162–5.CrossRefPubMed

18.

Uko S, Soghier LM, Vega M, Marsh J, Reinersman GT, Herring L, et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics. 2006;117(4):1243–52.CrossRefPubMed

19.

Manzoni P, Arisio R, Mostert M, Leonessa M, Farina D, Latino MA, et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics. 2006;117:e22–32.CrossRefPubMed

20.

McCrossan BA, McHenry E, O'Neill F, Ong G, Sweet DG. Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection. Arch Dis Child Fetal Neonatal Ed. 2007;92(6):F454–8.CrossRefPubMedPubMedCentral

21.

Weitkamp JH, Ozdas A, LaFleur B, Potts AL. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol. 2008;28(6):405–11. https://doi.org/10.1038/sj.jp.7211914.CrossRefPubMed

22.

Rueda K, Moreno MT, Espinosa M, Sáez-Llorens X. Impact of routine fluconazole prophylaxis for premature infants with birth weights of less than 1250 grams in a developing country. Pediatr Infect Dis J. 2010;29(11):1050–2. https://doi.org/10.1097/INF.0b013e3181e9dea2.PubMedCrossRef

23.

Rolnitsky A, Levy I, Sirota L, Shalit I, Klinger G. Targeted fluconazole prophylaxis for high-risk very low birth weight infants. Eur J Pediatr. 2012;171(10):1481–7.CrossRefPubMed

24.

Ericson JE, Benjamin DK Jr. Fluconazole prophylaxis for prevention of invasive candidiasis in infants. Curr Opin Pediatr. 2014;26(2):151–6. https://doi.org/10.1097/MOP.0000000000000060.CrossRefPubMedPubMedCentral

25.

Pappas PG, Kauffman CA, Andes D, Benjamin DK J, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.CrossRefPubMed

26.

Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, et al. European Society of Clinical Microbiology and Infectious Diseases guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18(Suppl 7):38–52.CrossRefPubMed

27.

Rios JFDS, Camargos PAM, Corrêa LP, Romanelli RMC. Fluconazole prophylaxis in preterm infants: a systematic review. Braz J Infect Dis. 2017;21(3):333–8. https://doi.org/10.1016/j.bjid.2017.01.008.CrossRefPubMed

28.

Clerihew L, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2007 (4):CD003850.

29.

• Kaufman DA, Cuff AL, Wamstad JB, et al. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr. 2011;158:759–65. This long-term follow-up study of VLBW infants given fluconazole CrossRefPubMed

30.

Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis. 2012 Nov 15;55(10):1352–61. https://doi.org/10.1093/cid/cis697.CrossRefPubMedPubMedCentral

31.

Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373(15):1445–56. https://doi.org/10.1056/NEJMra1315399.CrossRefPubMed

32.

Pfaller MA, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol. 2009;47(10):3185–90. https://doi.org/10.1128/JCM.00946-09.CrossRefPubMedPubMedCentral

33.

Manzoni P, Leonessa M, Galletto P, Latino MA, Arisio R, Maule M, et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J. 2008;27:731–7.CrossRefPubMed

34.

Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014 Jun;33(6):919–26. https://doi.org/10.1007/s10096-013-2027-1.CrossRefPubMed

35.

Swanson JR, Vergales J, Kaufman DA, Sinkin RA. Cost analysis of fluconazole prophylaxis for prevention of neonatal invasive candidiasis. Pediatr Infect Dis J. 2016;35(5):519–23. https://doi.org/10.1097/INF.0000000000001068.CrossRefPubMed

36.

Martin A, Pappas A, Lulic-Botica M, Natarajan G. Impact of ‘targeted’ fluconazole prophylaxis for preterm neonates: efficacy of a highly selective approach? J Perinatol. 2012;32(1):21–6. https://doi.org/10.1038/jp.2011.27.CrossRefPubMed

37.

Ozturk MA, Gunes T, Koklu E, Cetin N, Koc N. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses. 2006;49(6):484–92.CrossRefPubMed

38.

Ganesan K, Harigopal S, Neal T, Yoxall CW. Prophylactic oral nystatin for preterm babies under 33 weeks’ gestation decreases fungal colonisation and invasive fungaemia. Arch Dis Child Fetal Neonatal Ed. 2009 Jul;94(4):F275–8. https://doi.org/10.1136/adc.2008.145359.CrossRefPubMed

39.

Howell A, Isaacs D, Halliday R, Australasian Study Group for Neonatal Infections. Oral nystatin prophylaxis and neonatal fungal infections. Arch Dis Child Fetal Neonatal Ed. 2009;94(6):F429–33. https://doi.org/10.1136/adc.2008.157123.CrossRefPubMed

40.

Chen J, Yu X, Zhou Y, Zhang Y, Zhu J, Xie L, et al. Integrated measures for prevention of invasive Candida infections in preterm infants in a Chinese neonatal intensive care unit. Am J Infect Control. 2015;43(12):1321–5. https://doi.org/10.1016/j.ajic.2015.07.011.CrossRefPubMed

Titel: Prevention of Invasive Candidiasis in Premature Neonates: Administering Fluconazole or Not?
verfasst von: Daniele Donà
Dora Luise
Eugenio Baraldi
Ursula Trafojer
Publikationsdatum: 09.05.2018
Verlag: Springer US
Erschienen in: Current Fungal Infection Reports / Ausgabe 2/2018
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-018-0312-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prevention of Invasive Candidiasis in Premature Neonates: Administering Fluconazole or Not?

Abstract

Purpose of the Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of the Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Fungal Eye Infections: New Hosts, Novel Emerging Pathogens but No New Treatments?

PCR-Based Methods for the Diagnosis of Invasive Candidiasis: Are They Ready for Use in the Clinic?

Candidiasis of the Central Nervous System in Neonates and Children With Primary Immunodeficiencies

Antifungal Prophylaxis in Children Receiving Antineoplastic Chemotherapy

The Black Yeasts: an Update on Species Identification and Diagnosis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin